-
1
-
-
0034971264
-
Why there are two cyclooxygenase isozymes
-
Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest. 2001;107:1491-1495.
-
(2001)
J Clin Invest
, vol.107
, pp. 1491-1495
-
-
Smith, W.L.1
Langenbach, R.2
-
2
-
-
3042564321
-
Prostaglandins, aspirin and other NSAIDs
-
Goldman L, Ausiello D, eds. London: Elsevier Science
-
FitzGerald GA. Prostaglandins, aspirin and other NSAIDs. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine, 22nd ed. London: Elsevier Science; 2004:155-161.
-
(2004)
Cecil Textbook of Medicine, 22nd Ed.
, pp. 155-161
-
-
FitzGerald, G.A.1
-
3
-
-
0037108979
-
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression
-
Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926-13931.
-
(2002)
Proc Natl Acad Sci U S A
, vol.99
, pp. 13926-13931
-
-
Chandrasekharan, N.V.1
Dai, H.2
Roos, K.L.3
-
4
-
-
0034931501
-
Genetic and pharmacological analysis of prostanoid receptor function
-
Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108:25-30.
-
(2001)
J Clin Invest
, vol.108
, pp. 25-30
-
-
Narumiya, S.1
FitzGerald, G.A.2
-
5
-
-
0034527045
-
The fight against rheumatism: From willow bark to COX-1 sparing drugs
-
Vane JR. The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol. 2000;51(4 Pt 1):573-586.
-
(2000)
J Physiol Pharmacol
, vol.51
, Issue.4 PART 1
, pp. 573-586
-
-
Vane, J.R.1
-
6
-
-
0036083196
-
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice
-
Sigthorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002;122:1913-1923.
-
(2002)
Gastroenterology
, vol.122
, pp. 1913-1923
-
-
Sigthorsson, G.1
Simpson, R.J.2
Walley, M.3
-
7
-
-
0033577982
-
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
-
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899 [Published erratum appears in N Engl J Med. 1999;341:548].
-
(1999)
N Engl J Med
, vol.340
, pp. 1888-1899
-
-
Wolfe, M.M.1
Lichtenstein, D.R.2
Singh, G.3
-
8
-
-
0033577982
-
-
Published erratum appears
-
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899 [Published erratum appears in N Engl J Med. 1999;341:548].
-
(1999)
N Engl J Med
, vol.341
, pp. 548
-
-
-
9
-
-
0035112660
-
Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient
-
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high risk patient. Gastroenterology. 2001;120:594-606.
-
(2001)
Gastroenterology
, vol.120
, pp. 594-606
-
-
Laine, L.1
-
10
-
-
0242690224
-
COX-2 and beyond: Approaches to prostaglandin inhibition in human disease
-
FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2:879-890.
-
(2003)
Nat Rev Drug Discov
, vol.2
, pp. 879-890
-
-
FitzGerald, G.A.1
-
11
-
-
0035833502
-
The coxibs, selective inhibitors of cyclooxygenase-2
-
FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433-442.
-
(2001)
N Engl J Med
, vol.345
, pp. 433-442
-
-
FitzGerald, G.A.1
Patrono, C.2
-
12
-
-
0034707105
-
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
-
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
-
(2000)
N Engl J Med
, vol.343
, pp. 1520-1528
-
-
Bombardier, C.1
Laine, L.2
Reicin, A.3
-
13
-
-
0036606889
-
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
-
Juni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ. 2002;324:1287-1288.
-
(2002)
BMJ
, vol.324
, pp. 1287-1288
-
-
Juni, P.1
Rutjes, A.W.2
Dieppe, P.A.3
-
14
-
-
0034644396
-
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
-
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
-
(2000)
JAMA
, vol.284
, pp. 1247-1255
-
-
Silverstein, F.E.1
Faich, G.2
Goldstein, J.L.3
-
15
-
-
0141962671
-
Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: Results of a 26-week trial
-
Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford). 2003;42:1207-1215.
-
(2003)
Rheumatology (Oxford)
, vol.42
, pp. 1207-1215
-
-
Pavelka, K.1
Recker, D.P.2
Verburg, K.M.3
-
16
-
-
0041571903
-
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events
-
Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am Gastroenterol. 2003;98:1725-1733.
-
(2003)
Am Gastroenterol
, vol.98
, pp. 1725-1733
-
-
Hunt, R.H.1
Harper, S.2
Watson, D.J.3
-
17
-
-
0037065502
-
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
-
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86 [Published erratum appears in BMJ. 2002;324:141].
-
(2002)
BMJ
, vol.324
, pp. 71-86
-
-
-
18
-
-
0037065502
-
-
Published erratum appears
-
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86 [Published erratum appears in BMJ. 2002;324:141].
-
(2002)
BMJ
, vol.324
, pp. 141
-
-
-
19
-
-
0037442069
-
Parsing an enigma: The pharmacodynamics of aspirin resistance
-
FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361:542-544.
-
(2003)
Lancet
, vol.361
, pp. 542-544
-
-
FitzGerald, G.A.1
-
20
-
-
0033524421
-
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
-
McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96:272-277.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 272-277
-
-
McAdam, B.F.1
Catella-Lawson, F.2
Mardini, I.A.3
-
21
-
-
0037134011
-
Role of prostacyclin in the cardiovascular response to thromboxane A2
-
Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
-
(2002)
Science
, vol.296
, pp. 539-541
-
-
Cheng, Y.1
Austin, S.C.2
Rocca, B.3
-
22
-
-
0030816051
-
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
-
Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388:678-682.
-
(1997)
Nature
, vol.388
, pp. 678-682
-
-
Murata, T.1
Ushikubi, F.2
Matsuoka, T.3
-
24
-
-
0023137593
-
Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
-
Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-186.
-
(1987)
Blood
, vol.69
, pp. 180-186
-
-
Reilly, I.A.1
FitzGerald, G.A.2
-
25
-
-
0035924765
-
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin
-
Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
-
(2001)
N Engl J Med
, vol.345
, pp. 1809-1817
-
-
Catella-Lawson, F.1
Reilly, M.P.2
Kapoor, S.C.3
-
26
-
-
0042416748
-
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs
-
Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation. 2003;108:1191-1195.
-
(2003)
Circulation
, vol.108
, pp. 1191-1195
-
-
Kurth, T.1
Glynn, R.J.2
Walker, A.M.3
-
27
-
-
0037442182
-
Effect of ibuprofen on cardioprotective effect of aspirin
-
MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;3361:573-574.
-
(2003)
Lancet
, vol.3361
, pp. 573-574
-
-
MacDonald, T.M.1
Wei, L.2
-
28
-
-
0344005434
-
Aspirin, ibuprofen, and mortality after myocardial infarction: Retrospective cohort study
-
Curtis JP, Wang Y, Portnay EL, et al. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ. 2003;327:1322-1323.
-
(2003)
BMJ
, vol.327
, pp. 1322-1323
-
-
Curtis, J.P.1
Wang, Y.2
Portnay, E.L.3
-
29
-
-
0037368116
-
Rofecoxib exerts no effect on platelet plug formation in healthy volunteers
-
Homoncik M, Malec M, Marsik C, et al. Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol. 2003;21:229-231.
-
(2003)
Clin Exp Rheumatol
, vol.21
, pp. 229-231
-
-
Homoncik, M.1
Malec, M.2
Marsik, C.3
-
30
-
-
0033665248
-
Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
-
Leese P, Hubbard R, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124-132.
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 124-132
-
-
Leese, P.1
Hubbard, R.2
Karim, A.3
-
31
-
-
0037568022
-
Characterization of etoricoxib, a novel, selective COX-2 inhibitor
-
Dallob A, Hawkey CJ, Greenberg H, et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol. 2003;43:573-585.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 573-585
-
-
Dallob, A.1
Hawkey, C.J.2
Greenberg, H.3
-
32
-
-
0036289132
-
Valdecoxib does not impair platelet function
-
Leese PT, Talwalker S, Kent JD, et al. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20:275-281.
-
(2002)
Am J Emerg Med
, vol.20
, pp. 275-281
-
-
Leese, P.T.1
Talwalker, S.2
Kent, J.D.3
-
33
-
-
0037407092
-
The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: Results of a randomized controlled trial
-
Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol. 2003;43:504-513.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 504-513
-
-
Leese, P.T.1
Recker, D.P.2
Kent, J.D.3
-
34
-
-
0035807799
-
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
-
Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci U S A. 2001;98:14583-14588.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 14583-14588
-
-
Ouellet, M.1
Riendeau, D.2
Percival, M.D.3
-
35
-
-
0034943759
-
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis
-
McEntegart A, Capell HA, Creran C, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology. 2001;40:640-644.
-
(2001)
Rheumatology
, vol.40
, pp. 640-644
-
-
McEntegart, A.1
Capell, H.A.2
Creran, C.3
-
36
-
-
0037149297
-
Relative risk of cardiovascular events in patients with rheumatoid arthritis
-
DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol. 2002;89:33D-8D.
-
(2002)
Am J Cardiol
, vol.89
-
-
DeMaria, A.N.1
-
37
-
-
12144290072
-
Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
-
Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109:1468-1471.
-
(2004)
Circulation
, vol.109
, pp. 1468-1471
-
-
Capone, M.L.1
Tacconelli, S.2
Sciulli, M.G.3
-
38
-
-
0037635061
-
Efficacy and safety of the cyclooxygenase 2 inhibitors paracoxib and valdecoxib in patients undergoing coronary artery bypass surgery
-
Ott E, Nussmeier NA, Duke PC, et al. ., for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group; Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyclooxygenase 2 inhibitors paracoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481-1492.
-
(2003)
J Thorac Cardiovasc Surg
, vol.125
, pp. 1481-1492
-
-
Ott, E.1
Nussmeier, N.A.2
Duke, P.C.3
-
39
-
-
2642538969
-
Lumiracoxib (Novartis)
-
Ding C, Jones G. Lumiracoxib (Novartis). IDrugs. 2002;5:1168-1172.
-
(2002)
IDrugs
, vol.5
, pp. 1168-1172
-
-
Ding, C.1
Jones, G.2
-
40
-
-
0142120428
-
Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program
-
Weir MR, Sperling RS, Reicin A, et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003;146:591-604.
-
(2003)
Am Heart J
, vol.146
, pp. 591-604
-
-
Weir, M.R.1
Sperling, R.S.2
Reicin, A.3
-
41
-
-
0041562646
-
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib
-
White WB, Faich G, Borer JS, et al. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003;92:411-418.
-
(2003)
Am J Cardiol
, vol.92
, pp. 411-418
-
-
White, W.B.1
Faich, G.2
Borer, J.S.3
-
42
-
-
0028580588
-
Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
-
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289-300.
-
(1994)
Ann Intern Med
, vol.121
, pp. 289-300
-
-
Johnson, A.G.1
Nguyen, T.V.2
Day, R.O.3
-
43
-
-
0031983792
-
NSAIDs and blood pressure. Clinical importance for older patients
-
Johnson AG. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging. 1998;12:17-27.
-
(1998)
Drugs Aging
, vol.12
, pp. 17-27
-
-
Johnson, A.G.1
-
44
-
-
0036308753
-
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II
-
Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69 [Published erratum appears in J Clin Invest. 2002;110:419].
-
(2002)
J Clin Invest
, vol.110
, pp. 61-69
-
-
Qi, Z.1
Hao, C.M.2
Langenbach, R.I.3
-
45
-
-
0036321987
-
-
Published erratum appears
-
Qi Z, Hao CM, Langenbach RI, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002;110:61-69 [Published erratum appears in J Clin Invest. 2002;110:419].
-
(2002)
J Clin Invest
, vol.110
, pp. 419
-
-
-
46
-
-
0036300898
-
The choreography of cyclooxygenases in the kidney
-
FitzGerald GA. The choreography of cyclooxygenases in the kidney. J Clin Invest. 2002;110:33-34.
-
(2002)
J Clin Invest
, vol.110
, pp. 33-34
-
-
FitzGerald, G.A.1
-
48
-
-
0035853050
-
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice
-
Pratico D, Tillmann C, Zhang Z, et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358-3363.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 3358-3363
-
-
Pratico, D.1
Tillmann, C.2
Zhang, Z.3
|